GW PHARMA-ADR (GWPH) Upgraded by Zacks to OUTPERFORM
Zacks Investment Research upgraded shares of GW PHARMA-ADR (GWPH) from NEUTRAL to OUTPERFORM on October 02, 2014, with a target price of $96.40. GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. […]